Clinical trial
TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non…
NCT00349219 · National Cancer Institute, Naples, Other · Completed
Key facts
| NCT number | NCT00349219 |
|---|---|
| Title | TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer |
| Official title | An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer |
| Acronym | TORCH |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Collaborators | San Giuseppe Moscati Hospital Princess Margaret Hospital, Canada University of Alberta University of Campania Luigi Vanvitelli |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Advanced Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | erlotinib, cisplatin, gemcitabine |
| Enrollment | 760 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2011 |
| Completion | Jun 1, 2012 |
| First posted | Jul 6, 2006 |
| Last update posted | Jan 15, 2016 |
| Countries | Canada, Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: